Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and distribution of non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical… Read more
Endonovo Therapeutics Inc (ENDV) - Total Assets
Latest total assets as of June 2025: $17.95K USD
Based on the latest financial reports, Endonovo Therapeutics Inc (ENDV) holds total assets worth $17.95K USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Endonovo Therapeutics Inc - Total Assets Trend (2009–2024)
This chart illustrates how Endonovo Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Endonovo Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Endonovo Therapeutics Inc's total assets of $17.95K consist of 91.9% current assets and 8.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Endonovo Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Endonovo Therapeutics Inc's current assets represent 91.9% of total assets in 2024, a decrease from 95.8% in 2009.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 20.8% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Endonovo Therapeutics Inc Competitors by Total Assets
Key competitors of Endonovo Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Endonovo Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Endonovo Therapeutics Inc generates 0.52x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Endonovo Therapeutics Inc is currently not profitable relative to its asset base.
Endonovo Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.00 | 0.00 | 0.00 |
| Quick Ratio | 0.00 | 0.00 | 0.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-27.74 Million | $ -25.70 Million | $ -15.33 Million |
Endonovo Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Endonovo Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 2.65 |
| Asset Growth Rate (YoY) | -97.0% |
| Total Assets | $19.29K |
| Market Capitalization | $51.10K USD |
Valuation Analysis
Premium Asset Valuation: The market values Endonovo Therapeutics Inc's assets at a significant premium ( 2.65x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Endonovo Therapeutics Inc's assets decreased by 97.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Endonovo Therapeutics Inc (2009–2024)
The table below shows the annual total assets of Endonovo Therapeutics Inc from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $19.29K | -96.98% |
| 2023-12-31 | $639.66K | -50.08% |
| 2022-12-31 | $1.28 Million | -36.17% |
| 2021-12-31 | $2.01 Million | -23.01% |
| 2020-12-31 | $2.61 Million | -20.39% |
| 2019-12-31 | $3.27 Million | -22.81% |
| 2018-12-31 | $4.24 Million | -8.02% |
| 2017-12-31 | $4.61 Million | +1347.30% |
| 2016-12-31 | $318.68K | +319.15% |
| 2015-12-31 | $76.03K | +66.77% |
| 2014-12-31 | $45.59K | -38.05% |
| 2013-12-31 | $73.59K | -5.77% |
| 2012-12-31 | $78.10K | +6.62% |
| 2011-12-31 | $73.25K | -56.38% |
| 2010-12-31 | $167.95K | -30.02% |
| 2009-12-31 | $240.00K | -- |